Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisagenlecleucel in relapsed or refractory follicular lymphoma
2023-508127-13-00Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in follicular lymphoma (FL), sponsored by Novartis. Primary endpoint: Complete response rate. Started Feb 2024; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-508127-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508127-13-00.